Trial reportInvestigational new drugs2008
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
Trial report in Investigational new drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Anlotinib combined with chemoradiotherapy for postoperative isolated lymph node recurrence of ESCC: a phase II study.Frontiers in immunology · 2026Trial
- Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Early-onset duodenal perforation during bevacizumab-containing chemotherapy in a patient with ovarian cancer: a case report.Journal of pharmaceutical health care and sciences · 2026Article
- Article
- Optimal Delivery of Pain Management in Schwannomatosis: A Literature Review.Therapeutics and clinical risk management · 2025Review
- Esophageal Ulcer After Intravitreal Ranibizumab Injection in a Patient With Age-Related Macular Degeneration.Gastroenterology research · 2023Article
- Gastrointestinal injury induced by immunomodulators: A review article.Therapeutic advances in gastroenterology · 2023Review
- Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review.World journal of gastrointestinal endoscopy · 2022Article
- Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.Internal medicine (Tokyo, Japan) · 2021Article
- Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors: association with the use of molecular-targeted agents.Journal of radiation research · 2020Article
- Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer.Case reports in oncological medicine · 2020Article
- Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.Journal of pediatric hematology/oncology · 2018Article
- Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.Investigational new drugs · 2018Article
- Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study.PloS one · 2017Article
- Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.BMC medicine · 2016Review
- Rectal cancer and Fournier's gangrene - current knowledge and therapeutic options.World journal of gastroenterology · 2015Review
- Use of bevacizumab in recurrent glioblastoma.CNS oncology · 2015Review
- Cetuximab-induced esophageal ulcer: the first report in literature.The Libyan journal of medicine · 2014Article
- Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.